A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus

Trial Profile

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CANVAS
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 12 Apr 2018 According to a Janssen pharmaceuticals media release, data of an additional analysis from the landmark CANVAS Program were presented at the 2018 National Kidney Foundation's Spring Clinical Meetings
    • 12 Apr 2018 Results of an additional analysis from the landmark CANVAS Program published in the Janssen pharmaceuticals Media Release
    • 11 Mar 2018 Results of an exploratory analysis assessing the effects of canagliflozin on heart failure and on a range of efficacy and safety outcomes among CANVAS Program participants (CANVAS and CANVAS-R; n=10142) with and without a history of heart failure at baseline, published in the Circulation Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top